JP2000517165A - 新規な脂質キナーゼ - Google Patents
新規な脂質キナーゼInfo
- Publication number
- JP2000517165A JP2000517165A JP10500305A JP50030598A JP2000517165A JP 2000517165 A JP2000517165 A JP 2000517165A JP 10500305 A JP10500305 A JP 10500305A JP 50030598 A JP50030598 A JP 50030598A JP 2000517165 A JP2000517165 A JP 2000517165A
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- kinase
- cell
- nucleic acid
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.図1に示すアミノ酸配列又はその相同体若しくはその類似体で示され、所 望により少なくとも1個のアミノ酸残基が欠失、置換又は付加により修飾されて もよいPI3キナーゼ活性を有し、かつ、白血球および/または黒色腫中で選択 的に発現性を示す自己燐酸化ポリペプチド、又は、その断片。 2.ポリペプチドが少なくとも1個の哺乳類p85アダプターポリペプチドと 会合する能力をもつ請求の範囲第1項記載のポリペプチド。 3.ポリペプチドが35〜45%のプロリン含量をもつドメインで特徴づけら れている請求の範囲第1又は2項に記載のポリペプチド。 4.プロリンリッチドメインが理想的には図1に示すプロテインの配列データ の292−311位にあるか、均等なPI3キナーゼ中の相同的/類似の部位で あってもよい請求の範囲第3項に記載のポリペプチド。 5.ポリペプチドが哺乳類由来のものであり、好ましくはヒト由来のものであ る請求の範囲第1〜4項のいずれかに記載のポリペプチド。 6.請求の範囲第1〜5項のいずれかに記載のポリペプチドをコードする核酸 。 7.核酸の配列がcDNAまたはゲノムDNAによるものである請求の範囲第 6項記載の核酸。 8.核酸がクローン化した組換え体ベクター中にある請求の範囲第6又は7項 に記載の核酸。 9.核酸またはその一部が、請求の範囲第1〜5項のいずれかに記載のポリペ プチドの組換えによる発現に適しているものである請求の範囲第6〜8項のいず れかに記載の核酸。 10.請求の範囲第1〜5項のいずれかに記載のポリペプチドの全部またはそ の一部を組換えにより合成するための請求の範囲第8または9項記載の発明の構 築物を用いてトランスフェクションあるいは形質転換した宿主細胞。 11.宿主細胞のセルラインが昆虫細胞系である請求の範囲第8項記載の宿主 細胞系。 12.p110δに対する抗体産生のための、請求の範囲第8又は9項に記載 の組換え体から発現したポリペプチドまたは請求の範囲第1〜5項のいずれかに 記載のポリペプチドの使用。 13.該抗体がモノクローナルである、請求の範囲第12項記載の抗体または その一部。 14.関連するポリペプチド並びに/またはそれをコードするmRNAおよび /若しくはcDNAのいずれかまたは両者の存在を検出・測定することからなる 請求の範囲第1〜5項のいずれかに記載のポリペプチドの組織特異的な発現の同 定方法。 15.cDNAが本発明の核酸の少なくとも1個の選択された部分にハイブリ ダイズするに適した少なくとも2種の核酸分子プライマーを結合することからな る請求の範囲第14項に記載の方法。 16.前記のプライマーを使用して、請求の範囲第6〜11項のいずれかに記 載の核酸の少なくとも一部を増幅または精製するための条件を提供することから なる請求の範囲第14または15項に記載の方法。 17.ELISA、ウエスタンブロット、免疫沈降または免疫蛍光を含む方法 により、前記ポリペプチドを検出するために請求の範囲第12または13項に記 載の抗体を使用することからなる請求の範囲第14に記載の方法。 18.ポリペプチドをインビトロまたはインビボで調節作用をもつ可能性のあ る被検物にさらし、次いで該ポリペプチドのキナーゼ活性を観察することからな る請求の範囲第1〜5項のいずれかに記載のポリペプチドのキナーゼ活性の調節 に有効な剤の同定方法。 19.潜在的拮抗剤をコンピューター化モデリングまたは従来の実験室的手法 を使用してスクリーニングすることからなる請求の範囲第18項に記載の方法。 20.請求の範囲第1〜5項のいずれかに記載のポリペプチドを発現する細胞 において、潜在的拮抗剤にさらし,該細胞の運動性をモニターすることからなる 請求の範囲第18または19項に記載の方法。 21.本発明のポリペプチドの活性の調節に有効な剤を含有してなる医薬また は獣医薬組成物。 22.所望により希釈剤、担体または賦形剤を含有し、および/または単位用 量形態である請求の範囲第21項に記載の医薬または獣医薬組成物。 23.細胞の集団を請求の範囲第1〜4項のいずれかに記載のポリペプチドま たはその拮抗薬もしくはその作用薬にさらすことからなる細胞の運動性の制御方 法。 24.細胞の運動性が、細胞を本発明のポリペプチドにさらすことにより増強 される請求の範囲第23項に記載の方法。 25.細胞の運動性の制御のための、請求の範囲第1〜5項のいずれかに記載 のポリペプチドの活性のブロックに有効な剤の使用。 26.細胞の運動性増強のための、請求の範囲第1〜5項のいずれかに記載の ポリペプチドの使用。 27.請求の範囲第6〜9項のいずれかに記載の核酸にハイブリダイズするに 適したアンチセンスオリゴヌクレオチド。 28.該オリゴヌクレオチドが本明細書に記載のように修飾されている請求の 範囲第27項に記載のアンチセンスオリゴヌクレオチド。 29.請求の範囲第27または28項に記載のアンチセンスオリゴヌクレオチ ドを含有してなる医薬/獣医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9611460.8A GB9611460D0 (en) | 1996-06-01 | 1996-06-01 | Novel lipid kinase |
GB9611460.8 | 1996-06-01 | ||
PCT/GB1997/001471 WO1997046688A1 (en) | 1996-06-01 | 1997-05-30 | Lipid kinase |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2000517165A true JP2000517165A (ja) | 2000-12-26 |
JP3902663B2 JP3902663B2 (ja) | 2007-04-11 |
Family
ID=10794609
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50030598A Expired - Fee Related JP3902663B2 (ja) | 1996-06-01 | 1997-05-30 | 新規な脂質キナーゼ |
Country Status (14)
Country | Link |
---|---|
US (4) | US6482623B1 (ja) |
EP (1) | EP0914448B1 (ja) |
JP (1) | JP3902663B2 (ja) |
CN (1) | CN1260360C (ja) |
AT (1) | ATE342364T1 (ja) |
AU (1) | AU719354B2 (ja) |
CA (1) | CA2256483C (ja) |
DE (1) | DE69736807T2 (ja) |
DK (1) | DK0914448T3 (ja) |
ES (1) | ES2274543T3 (ja) |
GB (1) | GB9611460D0 (ja) |
HK (1) | HK1020751A1 (ja) |
NZ (1) | NZ332634A (ja) |
WO (1) | WO1997046688A1 (ja) |
Families Citing this family (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9611460D0 (en) * | 1996-06-01 | 1996-08-07 | Ludwig Inst Cancer Res | Novel lipid kinase |
US5858753A (en) * | 1996-11-25 | 1999-01-12 | Icos Corporation | Lipid kinase |
AU781078B2 (en) * | 1996-11-25 | 2005-05-05 | Icos Corporation | Phosphatidylinositol 3-kinase P110 delta catalytic subunit |
AU2005201060B2 (en) * | 1996-11-25 | 2007-06-21 | Icos Corporation | Phosphatidylinositol 3-kinase P110 Delta Catalytic Subunit |
DE19860833C1 (de) * | 1998-12-30 | 2000-09-07 | Albrecht E Sippel | Methode zur zellulären High-Throughput(Hochdurchsatz)-Detektion von Rezeptor-Liganden-Interaktionen |
US6046049A (en) * | 1999-07-19 | 2000-04-04 | Isis Pharmaceuticals Inc. | Antisense modulation of PI3 kinase p110 delta expression |
AU3007001A (en) * | 1999-12-06 | 2001-06-12 | Axxima Pharmaceuticals Ag | Method for identification and quantification of kinase inhibitors |
CN1314480A (zh) * | 2000-03-22 | 2001-09-26 | 上海博德基因开发有限公司 | 一种新的多肽——人磷脂酰肌醇3激酶14和编码这种多肽的多核苷酸 |
EP1939203B1 (en) | 2000-04-25 | 2014-11-19 | ICOS Corporation | Inhibitors of human phosphatidyl-inositol 3-kinase delta isoform |
US6667300B2 (en) | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
US6518277B1 (en) * | 2000-04-25 | 2003-02-11 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
AU6523101A (en) * | 2000-05-31 | 2001-12-11 | Promega Corp | Assay for kinases and phosphatases |
US20050009124A1 (en) * | 2001-11-26 | 2005-01-13 | Echelon Biosciences Incorporated | Assays for detection of phosphoinositide kinase and phosphatase activity |
US7067269B2 (en) * | 2001-11-26 | 2006-06-27 | Echelon Biosciences, Inc. | Assaying apparatus, kit, and method for lipids and associated enzymes |
DE10232723A1 (de) * | 2002-07-16 | 2004-02-05 | MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH | Testsystem zur Auffindung von Inhibitoren von Inositolphosphatkinasen und Verwendungen dieser Inhibitoren für die Prophylaxe oder Therapie von proliferativen Erkrankungen |
US7429596B2 (en) * | 2003-06-20 | 2008-09-30 | The Regents Of The University Of California | 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof |
WO2005016348A1 (en) * | 2003-08-14 | 2005-02-24 | Icos Corporation | Method of inhibiting immune responses stimulated by an endogenous factor |
PT1761540T (pt) | 2004-05-13 | 2016-12-07 | Icos Corp | Quinazolinonas como inibidores de fosfatidilinositol-3-cinase delta humana |
CA2567883A1 (en) * | 2004-05-25 | 2005-12-15 | Icos Corporation | Methods for treating and/or preventing aberrant proliferation of hematopoietic cells |
JP2008520744A (ja) | 2004-11-19 | 2008-06-19 | ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア | 抗炎症性ピラゾロピリミジン |
US20080287469A1 (en) * | 2005-02-17 | 2008-11-20 | Diacovo Thomas G | Phosphoinositide 3-Kinase Inhibitors for Inhibiting Leukocyte Accumulation |
EA019961B1 (ru) * | 2006-04-04 | 2014-07-30 | Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния | Антагонисты киназы |
US7547760B2 (en) * | 2006-07-03 | 2009-06-16 | West Virginia University | Peptides and chemical compound for inhibition of SHP2 function |
SG178786A1 (en) | 2006-11-13 | 2012-03-29 | Lilly Co Eli | Thienopyrimidinones for treatment of inflammatory disorders and cancers |
EP3045458A1 (en) | 2007-03-23 | 2016-07-20 | Amgen, Inc | Heterocyclic compounds and their uses |
US20110160232A1 (en) * | 2007-10-04 | 2011-06-30 | Pingda Ren | Certain chemical entities and therapeutic uses thereof |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
JP5869222B2 (ja) | 2008-01-04 | 2016-02-24 | インテリカイン, エルエルシー | 特定の化学的実体、組成物および方法 |
US8993580B2 (en) | 2008-03-14 | 2015-03-31 | Intellikine Llc | Benzothiazole kinase inhibitors and methods of use |
EP2252293B1 (en) | 2008-03-14 | 2018-06-27 | Intellikine, LLC | Kinase inhibitors and methods of use |
US20110224223A1 (en) * | 2008-07-08 | 2011-09-15 | The Regents Of The University Of California, A California Corporation | MTOR Modulators and Uses Thereof |
US9096611B2 (en) | 2008-07-08 | 2015-08-04 | Intellikine Llc | Kinase inhibitors and methods of use |
JP5731978B2 (ja) | 2008-09-26 | 2015-06-10 | インテリカイン, エルエルシー | 複素環キナーゼ阻害剤 |
ES2570429T3 (es) | 2008-10-16 | 2016-05-18 | Univ California | Inhibidores de heteroaril quinasa de anillo condensado |
US8476282B2 (en) * | 2008-11-03 | 2013-07-02 | Intellikine Llc | Benzoxazole kinase inhibitors and methods of use |
US9492449B2 (en) | 2008-11-13 | 2016-11-15 | Gilead Calistoga Llc | Therapies for hematologic malignancies |
CN102271683B (zh) | 2008-11-13 | 2014-07-09 | 吉里德卡利斯托加公司 | 恶性血液病的治疗 |
WO2010083163A1 (en) * | 2009-01-13 | 2010-07-22 | Philadelphia Health And Education Corporation | The role of p110 delta signaling in morbidity and lung pathology induced by influenza virus infection |
WO2010111432A1 (en) | 2009-03-24 | 2010-09-30 | Calistoga Pharmaceuticals Inc. | Atropisomers of2-purinyl-3-tolyl-quinazolinone derivatives and methods of use |
AU2010239312A1 (en) | 2009-04-20 | 2011-11-10 | Gilead Calistoga Llc | Methods of treatment for solid tumors |
EP2427195B1 (en) | 2009-05-07 | 2019-05-01 | Intellikine, LLC | Heterocyclic compounds and uses thereof |
KR20140015121A (ko) | 2009-06-25 | 2014-02-06 | 암젠 인크 | 헤테로사이클릭 화합물 및 이의 용도 |
EP2445898A2 (en) | 2009-06-25 | 2012-05-02 | Amgen, Inc | 4h-pyrido[1,2-a]pyrimidin-4-one derivatives as pi3k inhibitors |
US8765940B2 (en) | 2009-06-25 | 2014-07-01 | Amgen Inc. | Heterocyclic compounds and their uses |
US20100331306A1 (en) | 2009-06-25 | 2010-12-30 | Amgen Inc. | Heterocyclic compounds and their uses |
KR20120049281A (ko) | 2009-07-21 | 2012-05-16 | 길리아드 칼리스토가 엘엘씨 | Pi3k 억제제를 이용한 간 장애의 치료 |
US8980899B2 (en) | 2009-10-16 | 2015-03-17 | The Regents Of The University Of California | Methods of inhibiting Ire1 |
JP2013514989A (ja) | 2009-12-18 | 2013-05-02 | アムジエン・インコーポレーテツド | 複素環式化合物およびその使用法 |
UY33304A (es) | 2010-04-02 | 2011-10-31 | Amgen Inc | Compuestos heterocíclicos y sus usos |
US8604032B2 (en) | 2010-05-21 | 2013-12-10 | Infinity Pharmaceuticals, Inc. | Chemical compounds, compositions and methods for kinase modulation |
EP2588473A1 (en) | 2010-06-30 | 2013-05-08 | Amgen Inc. | Nitrogen containing heterocyclic compounds as pik3 -delta inhibitors |
AU2011272862A1 (en) | 2010-06-30 | 2013-01-10 | Amgen Inc. | Heterocyclic compounds and their use as inhibitors of PI3K activity |
WO2012003278A1 (en) | 2010-06-30 | 2012-01-05 | Amgen Inc. | Quinolines as p13k inhibitors |
AU2011272853A1 (en) | 2010-07-01 | 2013-01-10 | Amgen Inc. | Heterocyclic compounds and their use as inhibitors of PI3K activity |
US8759371B2 (en) | 2010-07-01 | 2014-06-24 | Amgen Inc. | Heterocyclic compounds and their uses |
MX2012015134A (es) | 2010-07-02 | 2013-05-06 | Amgen Inc | Compuestos heterociclicos y su uso como inhibidores de actividad de pi3k. |
CA2815445A1 (en) | 2010-11-04 | 2012-05-10 | Amgen Inc. | 5 -cyano-4, 6 -diaminopyrimidine or 6 -aminopurine derivatives as pi3k-delta inhibitors |
AU2011326427B2 (en) | 2010-11-10 | 2016-01-07 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
EP2640715A1 (en) | 2010-11-17 | 2013-09-25 | Amgen Inc. | Quinoline derivatives as pik3 inhibitors |
AU2011349669A1 (en) | 2010-12-23 | 2013-07-11 | Amgen Inc. | Heterocyclic compounds and their uses |
UA115767C2 (uk) | 2011-01-10 | 2017-12-26 | Інфініті Фармасьютікалз, Інк. | Способи отримання ізохінолінонів і тверді форми ізохінолінонів |
JP6130305B2 (ja) | 2011-02-23 | 2017-05-17 | インテリカイン, エルエルシー | キナーゼ阻害剤の組み合わせおよびそれらの使用 |
AU2012284088B2 (en) | 2011-07-19 | 2015-10-08 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
WO2013012918A1 (en) | 2011-07-19 | 2013-01-24 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
CA2846431A1 (en) | 2011-08-29 | 2013-03-07 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
AU2012341028C1 (en) | 2011-09-02 | 2017-10-19 | Mount Sinai School Of Medicine | Substituted pyrazolo[3,4-D]pyrimidines and uses thereof |
CA2864305C (en) | 2012-03-05 | 2021-02-16 | Gilead Calistoga Llc | Polymorphic forms of (s)-2-(1-(9h-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3h)-one |
JP2015512451A (ja) | 2012-04-04 | 2015-04-27 | アムジエン・インコーポレーテツド | 複素環化合物およびその使用 |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
MX2015003874A (es) | 2012-09-26 | 2015-12-16 | Univ California | Modulacion de ire1. |
ES2685568T3 (es) | 2012-12-21 | 2018-10-10 | Gilead Calistoga Llc | Inhibidores de la isoquinolinona o quinazolinona fosfatidilinositol 3-quinasa |
AU2013364068B2 (en) | 2012-12-21 | 2016-10-20 | Gilead Calistoga Llc | Substituted pyrimidine aminoalkyl-quinazolones as phosphatidylinositol 3-kinase inhibitors |
US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
CA2915129C (en) | 2013-06-14 | 2021-07-27 | Gilead Sciences, Inc. | Phosphatidylinositol 3-kinase inhibitors |
CN105793255B (zh) | 2013-10-04 | 2018-11-16 | 无限药品股份有限公司 | 杂环化合物及其用途 |
WO2015051241A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
EP3083623A1 (en) | 2013-12-20 | 2016-10-26 | Gilead Calistoga LLC | Polymorphic forms of a hydrochloride salt of (s) -2-(9h-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3h) -one |
EP3083630B1 (en) | 2013-12-20 | 2019-08-21 | Gilead Calistoga LLC | Process methods for phosphatidylinositol 3-kinase inhibitors |
AU2015231413B2 (en) | 2014-03-19 | 2020-04-23 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds for use in the treatment of PI3K-gamma mediated disorders |
US20150320755A1 (en) | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
SG11201609877XA (en) | 2014-06-13 | 2016-12-29 | Gilead Sciences Inc | Phosphatidylinositol 3-kinase inhibitors |
CN104155440B (zh) * | 2014-07-16 | 2016-02-10 | 广东药学院 | p110δ及其抗体在特异性标记滋养层巨细胞(pTGC)中的应用 |
WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
KR20180058741A (ko) | 2015-09-14 | 2018-06-01 | 인피니티 파마슈티칼스, 인코포레이티드 | 이소퀴놀리논의 고체형, 그의 제조 방법, 이를 포함하는 조성물 및 이를 사용하는 방법 |
US10759806B2 (en) | 2016-03-17 | 2020-09-01 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors |
US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
KR20190033526A (ko) | 2016-06-24 | 2019-03-29 | 인피니티 파마슈티칼스, 인코포레이티드 | 병용 요법 |
US20240075093A1 (en) * | 2020-10-09 | 2024-03-07 | Virginia Tech Intellectual Properties, Inc. | Compositions and methods of treating a pi3k mediated disease |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3992788A (en) * | 1975-07-14 | 1976-11-23 | Orien William P | Insole and outsole construction for athletic (tennis) shoes, and the like |
US4603698A (en) * | 1984-05-09 | 1986-08-05 | Jaime Guttmann Cherniak | System of podiatric appliances independently adjustably securable on inner sole-like base plate |
GB8609998D0 (en) * | 1986-04-24 | 1986-05-29 | Andrews A C | Insoles for footwear |
US4841648A (en) * | 1988-02-29 | 1989-06-27 | Shaffer David E | Personalized insole kit |
GB9208135D0 (en) * | 1992-04-13 | 1992-05-27 | Ludwig Inst Cancer Res | Polypeptides having kinase activity,their preparation and use |
GB9611460D0 (en) * | 1996-06-01 | 1996-08-07 | Ludwig Inst Cancer Res | Novel lipid kinase |
KR0173096B1 (ko) * | 1996-11-11 | 1999-01-15 | 박인식 | 발 교정용 안창 |
US5858753A (en) * | 1996-11-25 | 1999-01-12 | Icos Corporation | Lipid kinase |
US6393736B1 (en) * | 2000-05-25 | 2002-05-28 | Greer Reed Biomedical, Llc | Adjustable brace orthotic and method of treating plantar fasciitis and related foot disorders |
US6854199B2 (en) * | 2001-09-28 | 2005-02-15 | Joseph Paul Polifroni | Layered arch support |
US6557273B2 (en) * | 2001-09-28 | 2003-05-06 | Joseph Paul Polifroni | Layered arch support and method of manufacture |
US7124520B2 (en) * | 2002-01-18 | 2006-10-24 | Pittsburgh Plastics Manufacturing, Inc. | Footwear insoles |
JP2004031574A (ja) * | 2002-06-25 | 2004-01-29 | Fuji Photo Film Co Ltd | プラスチックファイバーを用いた伝送装置 |
US20040194344A1 (en) * | 2003-04-05 | 2004-10-07 | Tadin Anthony G. | User-customizable insoles for footwear and method of customizing insoles |
US7210250B2 (en) * | 2005-06-07 | 2007-05-01 | Gallegos Alvaro Z | Multipiece footwear insole |
US20070039208A1 (en) * | 2005-08-22 | 2007-02-22 | Fila Luxembourg S.A.R.L. | Adaptable shoe having an expandable sole assembly |
US7900380B2 (en) * | 2005-10-13 | 2011-03-08 | Masterfit Enterprises Inc. | User moldable adjustable insert |
-
1996
- 1996-06-01 GB GBGB9611460.8A patent/GB9611460D0/en active Pending
-
1997
- 1997-05-30 DE DE69736807T patent/DE69736807T2/de not_active Expired - Lifetime
- 1997-05-30 DK DK97924137T patent/DK0914448T3/da active
- 1997-05-30 EP EP97924137A patent/EP0914448B1/en not_active Expired - Lifetime
- 1997-05-30 CA CA2256483A patent/CA2256483C/en not_active Expired - Fee Related
- 1997-05-30 WO PCT/GB1997/001471 patent/WO1997046688A1/en active IP Right Grant
- 1997-05-30 ES ES97924137T patent/ES2274543T3/es not_active Expired - Lifetime
- 1997-05-30 NZ NZ332634A patent/NZ332634A/xx not_active IP Right Cessation
- 1997-05-30 JP JP50030598A patent/JP3902663B2/ja not_active Expired - Fee Related
- 1997-05-30 AU AU29705/97A patent/AU719354B2/en not_active Ceased
- 1997-05-30 CN CNB971951519A patent/CN1260360C/zh not_active Expired - Fee Related
- 1997-05-30 US US09/194,640 patent/US6482623B1/en not_active Expired - Lifetime
- 1997-05-30 AT AT97924137T patent/ATE342364T1/de active
-
1999
- 1999-11-12 HK HK99105251A patent/HK1020751A1/xx not_active IP Right Cessation
-
2002
- 2002-06-03 US US10/162,160 patent/US6849420B2/en not_active Expired - Lifetime
-
2004
- 2004-08-20 US US10/922,748 patent/US20050064572A1/en not_active Abandoned
-
2005
- 2005-09-02 US US11/219,611 patent/US7422886B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US20030099627A1 (en) | 2003-05-29 |
US20050064572A1 (en) | 2005-03-24 |
WO1997046688A1 (en) | 1997-12-11 |
CN1260360C (zh) | 2006-06-21 |
EP0914448B1 (en) | 2006-10-11 |
CA2256483C (en) | 2010-06-22 |
EP0914448A1 (en) | 1999-05-12 |
JP3902663B2 (ja) | 2007-04-11 |
CA2256483A1 (en) | 1997-12-11 |
ATE342364T1 (de) | 2006-11-15 |
US6849420B2 (en) | 2005-02-01 |
US6482623B1 (en) | 2002-11-19 |
AU2970597A (en) | 1998-01-05 |
AU719354B2 (en) | 2000-05-04 |
DK0914448T3 (da) | 2007-02-12 |
GB9611460D0 (en) | 1996-08-07 |
HK1020751A1 (en) | 2000-05-19 |
DE69736807T2 (de) | 2007-08-16 |
US7422886B2 (en) | 2008-09-09 |
CN1220701A (zh) | 1999-06-23 |
NZ332634A (en) | 2000-09-29 |
US20060018893A1 (en) | 2006-01-26 |
DE69736807D1 (en) | 2006-11-23 |
ES2274543T3 (es) | 2007-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2000517165A (ja) | 新規な脂質キナーゼ | |
Domin et al. | Cloning of a human phosphoinositide 3-kinase with a C2 domain that displays reduced sensitivity to the inhibitor wortmannin | |
AU2001263952B2 (en) | Tumour suppressor and uses thereof | |
EP0781326A1 (en) | The irs family of genes | |
EP0870035A2 (en) | A novel protein kinase required for ras signal transduction | |
US20050271668A1 (en) | Janus family kinases and identification of immune modulators | |
JP2001523456A (ja) | 転写的に調節されたgタンパク質−共役受容体 | |
Tanaka et al. | Interaction of EphB2-tyrosine kinase receptor and its ligand conveys dorsalization signal in Xenopus laevis development | |
JPH07506969A (ja) | レセプタ型チロシンキナーゼ類似の分子 | |
EP1100929B1 (en) | Identification and functional characterization of a novel ribosomal s6 protein kinase | |
US6770467B2 (en) | Screening method for ligands with class II P13 kinase modulating activity | |
WO1996037610A2 (en) | Cck-4, a receptor tyrosine kinase, and methods for diagnosis and treatment of cck-4 signal transduction disorders | |
US6830909B1 (en) | Identification and functional characterization of a novel ribosomal S6 protein kinase | |
AU701901B2 (en) | Cytoplasmic tyrosine kinase | |
US20170145391A1 (en) | TRUNCATED VARIANT OF THE MAMMALIAN TARGET FOR RAPAMYCIN (mTOR) PROTEIN | |
Chu et al. | Identification and characterization of DBK, a novel putative serine/threonine protein kinase from human endothelial cells | |
JP2001503994A (ja) | チロシンリン酸化切断溝関連タンパク質(pstpip) | |
Astoul et al. | Evidence That SHIP-1 Contributes to | |
Marin-Hincapie | Biochemical and functional characterization of the Drosophila insulin receptor | |
CA2362936A1 (en) | A caspase activated protein kinase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040122 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060620 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060914 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20061219 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070104 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110112 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120112 Year of fee payment: 5 |
|
LAPS | Cancellation because of no payment of annual fees |